High-dose Interleukin-2 Therapy for Metastatic Renal Cell Carcinoma: A Contemporary Experience

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

E. Eisenhauer, P. Therasse, Jan Bogaerts et al. · European Journal of Cancer · 2008 · 29.5K citations

Medicine, Oncology, Treatment Planning +14

New Guidelines to Evaluate the Response to Treatment in Solid Tumors

Patrick Therasse, Susan G. Arbuck, Elizabeth A. Eisenhauer et al. · JNCI Journal of the National Cancer Institute · 2000 · 15.7K citations

Medicine, Oncology, Cancer Pharmacology +12

A Randomized Trial of Bevacizumab, an Anti–Vascular Endothelial Growth Factor Antibody, for Metastatic Renal Cancer

James Chih‐Hsin Yang, Leah Haworth, Richard M. Sherry et al. · New England Journal of Medicine · 2003 · 2.7K citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy.

G. Fyfe, Richard I. Fisher, S A Rosenberg et al. · Journal of Clinical Oncology · 1995 · 1.4K citations

Medicine, Oncology, Pharmacology +16

Recombinant Human Interleukin-2, Recombinant Human Interferon Alfa-2a, or Both in Metastatic Renal-Cell Carcinoma

Sylvie Négrier, Bernard Escudier, Christine Lasset et al. · New England Journal of Medicine · 1998 · 969 citations · Full text

Medicine, Oncology, Pharmacotherapy +14